CODA Biotherapeutics

6 articles with CODA Biotherapeutics

• 

  Top Life Sciences Startups to Watch in 2021

  1/6/2021

  BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.

• CODA Biotherapeutics Receives Grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) to Help Advance its Next-Generation Gene Therapy-Mediated Chemogenetic Platform

  11/10/2020

  NINDS Small Business Innovation Research grant of $670K over two years to support CODA's neuropathic pain program Company also selected for collaboration with NIH's National Center for Advancing Translational Science

• CODA Biotherapeutics Announces Research Collaboration With The Facial Pain Research Foundation

  5/20/2020

  Strategic partnership supports CODA's efforts to develop gene-therapy mediated treatments and cures for trigeminal neuralgia and related neuropathic pain   [20-May-2020]   SOUTH SAN FRANCISCO, Calif. , May 20, 2020 /PRNewswire/ -- CODA Biotherapeutics, Inc., a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform, today annou

• CODA Biotherapeutics Acquires Attenua and Three Clinical Stage Assets

  2/5/2020

  CODA Biotherapeutics, Inc., a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform, today announced it has completed the acquisition of Attenua, Inc.

• CODA Biotherapeutics Deepens Gene Therapy Expertise with Industry Veteran, Annahita Keravala, Ph.D., and Key Promotions

  11/21/2019

  Expansion and development of leadership team drives the company's chemogenetic gene therapy platform toward the clinic in initial core therapeutic areas of chronic neuropathic pain and focal epilepsy

• CODA Biotherapeutics Announces Series A Extension, Bringing Total Round to $34 Million

  11/5/2019

  Proceeds will advance company's chemogenetic gene therapy platform toward the clinic with an initial focus on chronic neuropathic pain and focal epilepsy